Drug class
Free-radical scavenger; antioxidant neuroprotective small molecule
Mechanism of action
The mechanism by which edaravone produces clinical benefit in amyotrophic lateral sclerosis (ALS) is not fully understood. It scavenges free radicals and may reduce oxidative stress and lipid peroxidation; these effects should not be equated with a proven disease-modifying molecular pathway.
General use cases
- Treatment of amyotrophic lateral sclerosis (ALS) in adults under the US product indication; the clinical benefit is described as slowing decline in physical function in the studied population
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
